New combo therapy aims to tackle advanced liver cancer
NCT ID NCT07587034
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a new way to treat intermediate and advanced liver cancer. It combines two liver-directed procedures (HAIC and TACE) with two drugs (apatinib and camrelizumab) to see if this approach works better than other combinations. The study will involve 315 adults with liver cancer who cannot have surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apatinib and camrelizumab
- What this could lead to
- If successful, this could lead to a more effective treatment strategy for people with intermediate to advanced liver cancer, potentially extending life and controlling tumor growth.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from the drugs and procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?